The Lancet HIV: High rates of recreational drug use among HIV-positive gay and bisexual men in the UK strongly linked with condomless sex

September 07, 2014

New research published in The Lancet HIV shows that polydrug use is common among HIV-positive men who have sex with men (MSM) [1] and is strongly linked to sex without a condom (condomless sex).

This is the largest questionnaire study of people living with HIV in the UK, accounting for about 5% of all HIV-diagnosed MSM in the UK. The findings show that half of MSM surveyed had used recreational drugs at least once in the previous 3 months [2]. About half of those who used drugs took three or more different types of drugs, while roughly a fifth said they had used five or more different drugs in the past 3 months. Condom use was markedly lower with increasing polydrug use. For example, over three-quarters of participants who said they had used five drugs or more in the past 3 months also reported condomless sex, compared with less than a quarter of those who reported no recent drug use.

"Our findings show that polydrug use and condomless sex are closely linked in HIV-positive MSM in the UK, and that polydrug users are likely to be a group at increased risk of transmission of HIV and other sexually transmitted infections (STIs)", explains lead author Ms Marina Daskalopoulou from University College London in the UK. [3]

"The majority of these men would not consider or self-refer to traditional harm reduction services. Our findings highlight the need for cross-agency collaboration between HIV treatment and drug support organisations to provide tailored services for HIV-positive MSM who use recreational drugs, and with national HIV and STI prevention programmes to address recreational drug use." [3]

The study collected self-reported data on the drug use and sexual behaviour of 2248 MSM with HIV during 2011-2012 who were enrolled as part of the ASTRA study. All men were aged 18 years or older and attending eight HIV outpatient clinics in the UK.

Increasing number of drugs used was linked to increasing prevalence of sex that could pose a risk of transmission of HIV or other STIs. For example, recent users of five or more drugs were far more likely than those with no recent drug use to have sex without a condom (78% vs 24%); to have condomless sex with a partner of HIV-negative or HIV-unknown status (25% vs 10%); and to have sex with a higher risk of transmitting HIV (16% vs 4%; having condomless sex with a partner of HIV-negative or HIV-unknown status if the participant is not on antiretroviral treatment, has detectable viral load, or another recent STI).

However, the authors point out that only a minority (15%) of HIV positive MSM reported condomless sex with a partner of HIV-unknown or HIV-negative status, and fewer (7%) reported higher-HIV-risk condom-less sex.

Writing in a linked Comment, Associate Professor Martin Holt, from the Centre for Social Research in Health at The University of New South Wales in Australia points out that, "Only (7%) of the 2248 MSM included in the analysis reported such high-HIV-risk sex. This finding is heartening, and suggests that most HIV-positive MSM take care to prevent HIV transmission. Only a small proportion, it seems, need assistance in negotiating sex, drugs, and HIV treatment... A culturally appropriate evidence-based response is needed to help reduce harm in the UK without further sensationalising the issue.
-end-
The Lancet HIV is a new journal launched in September 2014 and will build on The Lancet journals' rich history of publishing HIV/AIDS research to provide a reliable foundation for advocacy and for programmatic and political change. The journal publishes research articles, linked commentary, and correspondence related to previous content. The journal accepts clinical, epidemiological, operational, and implementation research submissions, unifying these disciplines across a single vision for the health of those living with HIV. See http://www.thelancet.com/hiv for more details.

Notes to Editors:

This study was funded by the National Institute for Health Research.

[1] MSM includes gay and bisexual men as well as those who have sex with men but do not identify themselves as gay or bisexual.

[2] Recreational drugs included: acid (lysergic acid diethylamide, LSD), magic mushrooms, anabolic steroids, cannabis (marijuana), cocaine (coke), crack, codeine, methamphetamine (crystal meth), ecstasy (E), GHB (liquid ecstasy) or GBL, heroin, ketamine (K), Khat (chat), mephedrone, morphine, opium, amyl nitrites (poppers), amphetamine (speed), and erectile dysfunction drugs sildenafil (Viagra) and tadalafil (Cialis).

[3] Quotes direct from author and cannot be found in text of Article.

The Lancet

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.